MEDICAL STUDENT AND RESEARCHER
GUANGZHOU, GUANGDONG | China
Main Specialties: Hematology & Oncology, Internal Medicine, Medical Genetics
Additional Specialties: ONCOLOGY AND HUMAN ANATOMY
I am Dattatreya Mukherjee, Medical student of Jinan University, Guangzhou, P.R China. My Best Field of Research Hematology, Cancer Stem Cell, Beta And Alfa Blocker Medicine, Cardiac Potassium Channel Control, Pathology, Anatomy, MRD in B cell ALL, Psychology. WINNER OF YOUNG SCIENTIST AWARD, IOSRD, USA. Trained in Dysphagia Control, Chemotherapy, Medical Adherence From Universities Of UK and Cancer Management From ASCO, USA. Article Writer in Micro bacterium and Brain Transplantation. Paper Presents at 2018 HAPS annual conference, Ohio, USA, THE OHIO STATE UNIVERSITY. I have published and presented MRD in B cell leukemia and AMG510 K ras inhibitor paper in INTERNATIONAL STEM CELL CONFERENCE In AMSTERDAM. MEMBER OF ASCO. MEMBER OF ROYAL COLLEGE OF PHYSICIANS, EUROPEAN SOCIETY OF ONCOLOGY, ROYAL COLLEGE OF SURGERY, BRITISH ASSOCIATION OF CANCER RESEARCH.
TOTAL SCIENTIFIC PAPAER PUBLISHED: 4
3 IN oncology (1 CONFERENCE PAPER, 2 JOURNAL PAPER)
1 IN HUMAN ANATOMY
REVIEWER OF ACTA SCIENTIFIC ONCOLOGY
AUTHOR OF TWO ARTICLES IN E MAGAZINE: YOUTH KI AWAAZ
RESEARCH INTEREST: ONCOLOGY, HEMATOLOGY, HUMAN ANATOMY
Primary Affiliation: JINAN UNIVERSITY - GUANGZHOU, GUANGDONG , China
IOSR-JDMS 2020 MAY 19,5(1)1-8
Objectives and Background:To describe clinical outcomes and prognosis i.e overall survival and relapse in the patients with paediatric B cell ALL (pBALL)with respect to minimal residual disease detection on day 15, day 29 and post consolidations in a tertiary care centre in eastern India. Minimal Residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Prognostic importance of MRD in paediatric ALL is well accepted all over the world. This is the study where 8 colour flow cytometry (FCM) is used to detect MRD to assestreatment, diagnosis and prognosis of BcellALL. Method:Our Study had been running on 52 paediatric patients with the age group of 1 to 12 years with the MRD analysis on day 15, day 29 and post consolidations and a follow-up of 3 years where we have used 8 colour FCM to detect the MRD analysis. FCM contains CD The patient has gone through a 3 years follow-up and number of patient relapse is determined..Result: The study includes 52 patients. In the 52 patients 59.6% patients are alive with a p value of 31. MRD was checked in every 15 th and the 29 th dayand post consolidation of the treatment where in day 15(p=23), 53.4% positive and 46.5% negative. In day 29(p=31), 22.5 positive and 77.5 negative, in post consolidation positive in 20% and Negative is 80%. MRD value below 0.01 is taken as negative and above is taken as positive. The overall survival(OS) is of 32.88+_ 8.59 with a 6 to 36 months duration. In relapse, no haemorrhagic relapse is found and 2 CNS relapse is found. Conclusion: It is a study of 52 patients of paediatric B cell ALL with a detection of MRD by FCM.MRD negative patient have a good prognosis and comparatively lower rate of relapse than the one with positive MRD. Effort should be made to adhere to recommendation of MRD testing in clinical guidelines.ARTICLE AVAILABLE AT IOSR-JDMS, RESEARCH GATE, ACADEMIA EDU AND GOOGLE
IOSR-JDMS 2020 MAY 19,4(2)11-15
Background: The good prognosis of paediatric B cell acute lymphoblastic leukaemia (pALL) is considered as a great progress of medical science in the field of oncology and haematology. Minimal Residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Prognostic importance of MRD in paediatric ALL is well accepted. This is the study where 8 colour flow cytometry (FCM) is used to detect MRD to asses treatment, diagnosis and prognosis of Bcell ALL. Method: Our Study has used 8 the marker. Result: The study includes 52 patients. In the 52 patients 59.6% patients are alive with a p value of 0.031. MRD was checked at 15 th , 29 th day and post consolidation of the treatment where in day 15 (p=0.023), 53.4% positive and 46.5% negative. In day 29 (p=0.031), 22.5% positive and 77.5% negative, in post consolidation positive in 20% and Negative is 80%. MRD value below 0.01 is considered as negative. The overall survival is of 32.88±8.59 months with 6 to 36 months duration. Conclusion: It is a study of 52 patients of paediatric B cell ALL with a detection of MRD by FCM. According to this study day 29 and post consolidation results of MRD show a significant change with that of day 15. This significant early MRD negativity has any role in relapse and prognosis will be look into future study.
International Stem Cell And Onology Conference, 2019, the Netherland, The Amsterdam
There are 3 types of RAS oncogene, K RAS, N RAS, H RAS. This RAS can be diagnosed through Real Time PCR. H RAS point mutation is responsible for bladder cancer whereas N RAS point mutation is responsible for Hematopoietic tumours. K RAS point mutation is most important and it cause NON SMALL CELL LUNG CANCER, Carcinoma of Colon, Carcinoma of pancreas. K RAS is the molecular on/off switch. When turned on, it recruits and activates proteins necessary for the proliferation of growth factor and their receptors’ signal such as c-Raf and PI 3-kinase. In Combination with GTP, KRAS possesses an intrinsic enzymatic activity which cleaves the terminal phosphate of the nucleotide, and finally make itself turn off. For over 30 years, the protein KRAS is a major challenge in drug design. So far, there is no approved therapy for patients with KRAS mutations, which comprise around 25% of patients with lung cancer. Achillis heel small molecules in K RAS G12C, subverting the native nucleotide preference to favour GDP over GTP and impairing binding to Raf. Dr. Nathanael S. Gray, in the Department of Cancer Biology at the Dana-Farber Cancer Institute, reported the synthesis of a GDP analogue(SML-8-73-1) and a prodrug derivative (SML-10-70-1), which were selective, direct-acting covalent inhibitors of the KRAS (G12C) mutant relative to wild-type Ras. An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, KRAS mutant-targeting AMG 510 selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the AMG 510 KRAS G12C inhibitor
KS Varma and Dattatreya Mukherjee. “Sciatic Nerve Bifurcation in the Gluteal Region”. EC Clinical and Experimental Anatomy 2.5 (2019): 201-203.
EC CLINICAL AND EXPERIMENTAL ANATOMY
Abstract Sciatic nerve is the longest and widest nerve in the human body. It originates from the sacral plexus from L4S3 spinal nerves in the form of two nerve trunks. Commonly sciatic nerve bifurcates at the apex of the popliteal fossa into Tibial nerve and Common peroneal nerve. In the cadaver, we present a rare variation of bifurcation of the sciatic nerve into Tibial nerve and Common peroneal nerve in the gluteal region passing above the piriformis muscle. This type of human has a great chance of piriformis syndrome and sciatica